Maximilian Julve
Seminars
Tuesday 17th November 2026
Trade-Offs Between Specificity, Potency, Scalability, & Safety in Current TIL Approaches
1:30 pm
As the field moves beyond melanoma, the need for optimized efficacy and safety is forcing a rethink of manufacturing strategies and delivery strategies.
This workshop addresses the growing recognition that current TIL strategies involve bulk TIL expansion, diluting tumor reactive potential and requiring high dose IL-2 for efficacy.
Key questions addressed in this workshop:
- Which tumor-infiltrating lymphocyte subsets are truly reactive rather than expanded bystanders?
- Do selection approaches such as PD-1 or neoantigen targeting enrich potency or accelerate exhaustion?
• How can next-generation approaches optimize safety vs. efficacy?
